Cargando…

Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study

INTRODUCTION: Primary breast cancer involving four or more axillary lymph nodes carries a poor prognosis. We hypothesized that use of an immunohistochemical biomarker scoring system could allow for identification of variable risk subgroups. METHODS: Patients with four or more positive axillary nodes...

Descripción completa

Detalles Bibliográficos
Autores principales: Crabb, Simon J, Bajdik, Chris D, Leung, Samuel, Speers, Caroline H, Kennecke, Hagen, Huntsman, David G, Gelmon, Karen A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374957/
https://www.ncbi.nlm.nih.gov/pubmed/18194560
http://dx.doi.org/10.1186/bcr1847
_version_ 1782154545691885568
author Crabb, Simon J
Bajdik, Chris D
Leung, Samuel
Speers, Caroline H
Kennecke, Hagen
Huntsman, David G
Gelmon, Karen A
author_facet Crabb, Simon J
Bajdik, Chris D
Leung, Samuel
Speers, Caroline H
Kennecke, Hagen
Huntsman, David G
Gelmon, Karen A
author_sort Crabb, Simon J
collection PubMed
description INTRODUCTION: Primary breast cancer involving four or more axillary lymph nodes carries a poor prognosis. We hypothesized that use of an immunohistochemical biomarker scoring system could allow for identification of variable risk subgroups. METHODS: Patients with four or more positive axillary nodes were identified from a clinically annotated tissue microarray of formalin-fixed paraffin-embedded primary breast cancers and randomized into a 'test set' and a 'validation set'. A prospectively defined prognostic scoring model was developed in the test set and was further assessed in the validation set combining expression for eight biomarkers by immunohistochemistry, including estrogen receptor, human epidermal growth factor receptors 1 and 2, carbonic anhydrase IX, cytokeratin 5/6, progesterone receptor, p53 and Ki-67. Survival outcomes were analyzed by the Kaplan–Meier method, log rank tests and Cox proportional-hazards models. RESULTS: A total of 313 eligible patients were identified in the test set for whom 10-year relapse-free survival was 38.3% (SEM 2.9%), with complete immunohistochemical data available for 227. Tumor size, percentage of positive axillary nodes and expression status for the progesterone receptor, Ki-67 and carbonic anhydrase IX demonstrated independent prognostic significance with respect to relapse-free survival. Our combined biomarker scoring system defined three subgroups in the test set with mean 10-year relapse-free survivals of 75.4% (SEM 7.0%), 35.3% (SEM 4.1%) and 19.3% (SEM 7.0%). In the validation set, differences in relapse-free survival for these subgroups remained statistically significant but less marked. CONCLUSION: Biomarkers assessed here carry independent prognostic value for breast cancer with four or more positive axillary nodes and identified clinically relevant prognostic subgroups. This approach requires refinement and validation of methodology.
format Text
id pubmed-2374957
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-23749572008-05-10 Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study Crabb, Simon J Bajdik, Chris D Leung, Samuel Speers, Caroline H Kennecke, Hagen Huntsman, David G Gelmon, Karen A Breast Cancer Res Research Article INTRODUCTION: Primary breast cancer involving four or more axillary lymph nodes carries a poor prognosis. We hypothesized that use of an immunohistochemical biomarker scoring system could allow for identification of variable risk subgroups. METHODS: Patients with four or more positive axillary nodes were identified from a clinically annotated tissue microarray of formalin-fixed paraffin-embedded primary breast cancers and randomized into a 'test set' and a 'validation set'. A prospectively defined prognostic scoring model was developed in the test set and was further assessed in the validation set combining expression for eight biomarkers by immunohistochemistry, including estrogen receptor, human epidermal growth factor receptors 1 and 2, carbonic anhydrase IX, cytokeratin 5/6, progesterone receptor, p53 and Ki-67. Survival outcomes were analyzed by the Kaplan–Meier method, log rank tests and Cox proportional-hazards models. RESULTS: A total of 313 eligible patients were identified in the test set for whom 10-year relapse-free survival was 38.3% (SEM 2.9%), with complete immunohistochemical data available for 227. Tumor size, percentage of positive axillary nodes and expression status for the progesterone receptor, Ki-67 and carbonic anhydrase IX demonstrated independent prognostic significance with respect to relapse-free survival. Our combined biomarker scoring system defined three subgroups in the test set with mean 10-year relapse-free survivals of 75.4% (SEM 7.0%), 35.3% (SEM 4.1%) and 19.3% (SEM 7.0%). In the validation set, differences in relapse-free survival for these subgroups remained statistically significant but less marked. CONCLUSION: Biomarkers assessed here carry independent prognostic value for breast cancer with four or more positive axillary nodes and identified clinically relevant prognostic subgroups. This approach requires refinement and validation of methodology. BioMed Central 2008 2008-01-14 /pmc/articles/PMC2374957/ /pubmed/18194560 http://dx.doi.org/10.1186/bcr1847 Text en Copyright © 2008 Crabb et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Crabb, Simon J
Bajdik, Chris D
Leung, Samuel
Speers, Caroline H
Kennecke, Hagen
Huntsman, David G
Gelmon, Karen A
Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study
title Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study
title_full Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study
title_fullStr Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study
title_full_unstemmed Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study
title_short Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study
title_sort can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? a tissue microarray feasibility study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374957/
https://www.ncbi.nlm.nih.gov/pubmed/18194560
http://dx.doi.org/10.1186/bcr1847
work_keys_str_mv AT crabbsimonj canclinicallyrelevantprognosticsubsetsofbreastcancerpatientswithfourormoreinvolvedaxillarylymphnodesbeidentifiedthroughimmunohistochemicalbiomarkersatissuemicroarrayfeasibilitystudy
AT bajdikchrisd canclinicallyrelevantprognosticsubsetsofbreastcancerpatientswithfourormoreinvolvedaxillarylymphnodesbeidentifiedthroughimmunohistochemicalbiomarkersatissuemicroarrayfeasibilitystudy
AT leungsamuel canclinicallyrelevantprognosticsubsetsofbreastcancerpatientswithfourormoreinvolvedaxillarylymphnodesbeidentifiedthroughimmunohistochemicalbiomarkersatissuemicroarrayfeasibilitystudy
AT speerscarolineh canclinicallyrelevantprognosticsubsetsofbreastcancerpatientswithfourormoreinvolvedaxillarylymphnodesbeidentifiedthroughimmunohistochemicalbiomarkersatissuemicroarrayfeasibilitystudy
AT kenneckehagen canclinicallyrelevantprognosticsubsetsofbreastcancerpatientswithfourormoreinvolvedaxillarylymphnodesbeidentifiedthroughimmunohistochemicalbiomarkersatissuemicroarrayfeasibilitystudy
AT huntsmandavidg canclinicallyrelevantprognosticsubsetsofbreastcancerpatientswithfourormoreinvolvedaxillarylymphnodesbeidentifiedthroughimmunohistochemicalbiomarkersatissuemicroarrayfeasibilitystudy
AT gelmonkarena canclinicallyrelevantprognosticsubsetsofbreastcancerpatientswithfourormoreinvolvedaxillarylymphnodesbeidentifiedthroughimmunohistochemicalbiomarkersatissuemicroarrayfeasibilitystudy